目的 观察注射用益气复脉（冻干）联合沙库巴曲缬沙坦治疗慢性心力衰竭的治疗效果。方法 选择2021年1月—2022年12月河北省退役军人总医院心内科、荣军二科收治的慢性心衰住院患者106例为研究对象，根据患者治疗方案不同分为对照组和试验组，每组各53例。对照组患者给予常规药物（袢利尿剂、螺内酯、β受体阻滞剂）＋沙库巴曲缬沙坦钠片（口服每次100 mg，每天2次，依据患者耐受程度，酌情增减剂量，最大剂量为每次200 mg）治疗，试验组患者在对照组基础上加用注射用益气复脉（冻干），注射用益气复脉（冻干）5.2 g溶于0.9%氯化钠注射液250 mL中，静脉滴注，每天1次。两组均治疗4周。对比两组临床疗效，比较治疗前后两组患者氨基端前心钠肽（NT-proBNP）、左室射血分数（LVEF）、6分钟步行试验距离（6MWD）、明尼苏达州心功能不全生命质量量表（MLHFQ）评分，同时观察两组患者的不良反应。结果 经过4周治疗后，试验组总有效率为88.68%，显著高于对照组的73.58%（P＜0.05）。治疗前两组患者NT-proBNP、LVEF、6MWD、MLHFQ评分比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者NT-proBNP及MLHFQ评分均较本组治疗前显著降低（P＜0.05），且试验组显著低于对照组（P＜0.05）；治疗后，两组患者LVEF和6MWD均较本组治疗前显著增加（P＜0.05），且试验组显著高于对照组（P＜0.05）。对照组发生1例不良反应，试验组未发生不良反应，两组比较，差异无统计学意义（P＞0.05）。结论 注射用益气复脉（冻干）联合沙库巴曲缬沙坦治疗慢性心力衰竭具有较好的临床疗效，且安全性较高。

Objective To observe the therapeutic effect of Yiqi Fumai Lyophilized Injection combined with sacubitril valsartan in treatment of chronic heart failure, and to evaluate the clinical efficacy. Methods A total of 106 hospitalized patients with chronic heart failure admitted to the Department of Cardiology and Department of Rongjun Second of Hebei Veterans General Hospital from January 2021 to December 2022 were selected as the research subjects. They were divided into control group and experimental group based on different treatment plans, with 53 patients in each group. The patients in the control group were given conventional drugs (loop diuretic, spironolactone, and β receptor blocker) ＋Sacubitril Valsartan Sodium Tablets (100 mg orally, twice a day, according to the patient's tolerance, increase or decrease the dose as appropriate, the maximum dose is 200 mg each time). On the basis of the control group, patients in the experimental group added Yiqi Fumai Lyophilized Injection. Each time, 5.2 g of Yiqi Fumai Lyophilized Injection was taken and dissolved in 250 mL of 0.9% Sodium Chloride Injection, intravenous drip, once a day. Both groups were treated for four weeks. The clinical efficacy of the two groups was compared, and the N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), 6-minute walk test distance (6MWD), and Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores of the two groups of patients were compared before and after treatment. At the same time, the adverse reactions of patients in the two groups were observed. Results After four weeks of treatment, the total effective rate of the experimental group was 88.68%, significantly higher than the control group's 73.58% (P＜0.05). Before treatment, there was no statistically significant difference in NT-proBNP, LVEF, 6MWD, and MLHFQ scores between the two groups of patients (P＞0.05). After treatment, the NT-proBNP and MLHFQ scores of both groups of patients were significantly lower than before treatment of same group (P＜0.05), and the experimental group was significantly lower than the control group (P＜0.05). After treatment, LVEF and 6MWD of both groups of patients significantly increased compared to before treatment in same group (P＜0.05), and the experimental group was significantly higher than the control group (P＜0.05). One patient experienced adverse reactions in the control group, while no patient experienced adverse reactions in the experimental group. There was no statistically significant difference between the two groups (P＞0.05). Conclusion The combination of Yiqi Fumai Lyophilized Injection and sacubitril valsartan has good clinical efficacy and high safety in the treatment of chronic heart failure.

邢台市重点研发计划自筹项目（2020ZC255）